FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108961893> ?p ?o ?g. }

• W2108961893 endingPage "478" @default.
• W2108961893 startingPage "474" @default.
• W2108961893 abstract "Abstract: Chronic allograft nephropathy is a major cause for allograft loss in renal transplantation. Sirolimus was recently introduced as a potent non‐nephrotoxic alternative to calcineurin inhibitors. In the present study, effects of a conversion protocol were investigated in pediatric chronic allograft nephropathy with declining glomerular filtration rate (GFR), defined by a Schwartz formula clearance below 60 mL/1.73 m 2 /min, steadily increasing serum creatinine and allograft biopsy. In eight children with a median age of 12.8 yr, sirolimus was started at median 32 months after transplantation with a loading dose of 0.24 mg/kg bodyweight (BW), followed by 0.2 mg/kgBW/day, aimed at trough levels of 15–20 ng/mL. Calcineurin inhibitors were reduced to 50% at the start of sirolimus and discontinued at median 7 days when target levels of sirolimus were reached. Following conversion, changes of GFR significantly stabilized (−2.9 vs. +0.4 mL/min/1.73 m 2 /month, p = 0.025). Individual GFR increased in five out of eight patients (p = 0.026), and only one child exhibited unaltered progression of graft failure. In the responders, mean serum creatinine improved by 0.3 mg/dL (p = 0.043). Effects were not dependent on GFR at conversion, or on time post‐transplantation. Blood pressure, hematological parameters and proteinuria remained stable during the observation period, and serum lipids increased transiently. About half of the children suffered from infectious complications. No child had to be taken off sirolimus; there was no graft loss during the observation period. In conclusion, conversion from calcineurin inhibitors to sirolimus is an effective protocol with tolerable side effects to stabilize renal graft function for at least one yr in the majority of children with biopsy‐proven chronic allograft nephropathy." @default.
• W2108961893 created "2016-06-24" @default.
• W2108961893 creator A5006813747 @default.
• W2108961893 creator A5009611229 @default.
• W2108961893 creator A5011003633 @default.
• W2108961893 creator A5028563660 @default.
• W2108961893 creator A5062922220 @default.
• W2108961893 creator A5068919447 @default.
• W2108961893 creator A5068954333 @default.
• W2108961893 date "2006-05-19" @default.
• W2108961893 modified "2023-10-15" @default.
• W2108961893 title "Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy" @default.
• W2108961893 cites W1481151593 @default.
• W2108961893 cites W1975439751 @default.
• W2108961893 cites W1976111198 @default.
• W2108961893 cites W1979629903 @default.
• W2108961893 cites W1995791071 @default.
• W2108961893 cites W2013815484 @default.
• W2108961893 cites W2016210923 @default.
• W2108961893 cites W2021516618 @default.
• W2108961893 cites W2023338965 @default.
• W2108961893 cites W2033453424 @default.
• W2108961893 cites W2040941418 @default.
• W2108961893 cites W2058640787 @default.
• W2108961893 cites W2060111012 @default.
• W2108961893 cites W2069470274 @default.
• W2108961893 cites W2078882959 @default.
• W2108961893 cites W2079955997 @default.
• W2108961893 cites W2085510251 @default.
• W2108961893 cites W2145337089 @default.
• W2108961893 cites W2170264508 @default.
• W2108961893 doi "https://doi.org/10.1111/j.1399-3046.2006.00503.x" @default.
• W2108961893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16856992" @default.
• W2108961893 hasPublicationYear "2006" @default.
• W2108961893 type Work @default.
• W2108961893 sameAs 2108961893 @default.
• W2108961893 citedByCount "19" @default.
• W2108961893 countsByYear W21089618932012 @default.
• W2108961893 countsByYear W21089618932013 @default.
• W2108961893 countsByYear W21089618932015 @default.
• W2108961893 countsByYear W21089618932017 @default.
• W2108961893 countsByYear W21089618932018 @default.
• W2108961893 countsByYear W21089618932021 @default.
• W2108961893 countsByYear W21089618932022 @default.
• W2108961893 crossrefType "journal-article" @default.
• W2108961893 hasAuthorship W2108961893A5006813747 @default.
• W2108961893 hasAuthorship W2108961893A5009611229 @default.
• W2108961893 hasAuthorship W2108961893A5011003633 @default.
• W2108961893 hasAuthorship W2108961893A5028563660 @default.
• W2108961893 hasAuthorship W2108961893A5062922220 @default.
• W2108961893 hasAuthorship W2108961893A5068919447 @default.
• W2108961893 hasAuthorship W2108961893A5068954333 @default.
• W2108961893 hasConcept C126189478 @default.
• W2108961893 hasConcept C126322002 @default.
• W2108961893 hasConcept C126894567 @default.
• W2108961893 hasConcept C128057223 @default.
• W2108961893 hasConcept C134018914 @default.
• W2108961893 hasConcept C141071460 @default.
• W2108961893 hasConcept C159641895 @default.
• W2108961893 hasConcept C2777921159 @default.
• W2108961893 hasConcept C2779458710 @default.
• W2108961893 hasConcept C2779561371 @default.
• W2108961893 hasConcept C2780091579 @default.
• W2108961893 hasConcept C2780303639 @default.
• W2108961893 hasConcept C2780306776 @default.
• W2108961893 hasConcept C2781184683 @default.
• W2108961893 hasConcept C2909675724 @default.
• W2108961893 hasConcept C2911091166 @default.
• W2108961893 hasConcept C31785415 @default.
• W2108961893 hasConcept C555293320 @default.
• W2108961893 hasConcept C71924100 @default.
• W2108961893 hasConcept C90924648 @default.
• W2108961893 hasConceptScore W2108961893C126189478 @default.
• W2108961893 hasConceptScore W2108961893C126322002 @default.
• W2108961893 hasConceptScore W2108961893C126894567 @default.
• W2108961893 hasConceptScore W2108961893C128057223 @default.
• W2108961893 hasConceptScore W2108961893C134018914 @default.
• W2108961893 hasConceptScore W2108961893C141071460 @default.
• W2108961893 hasConceptScore W2108961893C159641895 @default.
• W2108961893 hasConceptScore W2108961893C2777921159 @default.
• W2108961893 hasConceptScore W2108961893C2779458710 @default.
• W2108961893 hasConceptScore W2108961893C2779561371 @default.
• W2108961893 hasConceptScore W2108961893C2780091579 @default.
• W2108961893 hasConceptScore W2108961893C2780303639 @default.
• W2108961893 hasConceptScore W2108961893C2780306776 @default.
• W2108961893 hasConceptScore W2108961893C2781184683 @default.
• W2108961893 hasConceptScore W2108961893C2909675724 @default.
• W2108961893 hasConceptScore W2108961893C2911091166 @default.
• W2108961893 hasConceptScore W2108961893C31785415 @default.
• W2108961893 hasConceptScore W2108961893C555293320 @default.
• W2108961893 hasConceptScore W2108961893C71924100 @default.
• W2108961893 hasConceptScore W2108961893C90924648 @default.
• W2108961893 hasIssue "4" @default.
• W2108961893 hasLocation W21089618931 @default.
• W2108961893 hasLocation W21089618932 @default.
• W2108961893 hasOpenAccess W2108961893 @default.
• W2108961893 hasPrimaryLocation W21089618931 @default.
• W2108961893 hasRelatedWork W150091706 @default.

• next